Full-Time
Sales & Operational Planning Leader
Piramal Pharma
1,001-5,000 employees
CDMO and hospital generics, consumer health
Compensation Overview
CA$90k - CA$135k/yr
Aurora, ON, Canada
In Person
 Operations & Logistics (1) |
|---|
Get referred to Piramal Pharma
See people who can refer or advise you
- Expertise in demand planning, supply response, network optimization, capacity planning, and resource planning.
- Experience supporting demand plans, finite scheduling, consumption models, long-term capacity planning, network and production strategy optimization, new business or project integration, and finance reporting and forecasting.
- Experience using enterprise resource planning systems, particularly SAP, to automate supply chain activities and reporting.
- Knowledge of raw materials management, including forecasting, scheduling, working capital control, and obsolescence.
- Ability to maintain planning master-data integrity across cross-functional tools and systems.
- Ability to develop and optimize production and capacity plans while accounting for material, asset, manpower, and resource requirements.
- Ability to analyze demand and supply gaps, capacity utilization, execution risks, and contingency scenarios.
- Ability to maintain risk, contingency, and countermeasure plans supporting on-time-in-full and financial commitments.
- Support and facilitate the sales and operations planning process within a 24-month site horizon, including scenario planning and data synthesis for demand, supply, reconciliation, and executive review cycles.
- Facilitate planning discussions to gain consensus among functions and stakeholders.
- Drive full utilization of SAP enterprise resource planning capabilities to automate supply chain activities and reporting.
- Produce periodic sales and operations planning reports, including long-term capacity plans, utilization, and resource constraints.
- Maintain a production plan that supports the production schedule and identifies material, asset, and manpower requirements.
- Facilitate demand-and-supply matching and adjust plans or schedules to reflect resource availability.
- Optimize capacity plans for 24-month sales and operations planning and longer-term business planning; identify excess or insufficient capacity and manpower so corrective actions can be taken in advance.
- Propose scenarios and trade-offs during reconciliation and executive reviews to support capacity-allocation decisions among projects.
- Ensure forecasts are captured, aligned with capacity, and reviewed in supply-response meetings to optimize capacity and revenue.
- Provide capacity planning that incorporates all demand signals while working collaboratively with cross-functional teams.
- Provide insights and reports on capacity utilization, demand and supply gaps, execution risk, and scenario or contingency planning.
- Drive ideation with partner functions to optimize delivery, productivity, and cost.
- Perform other duties as assigned.
Piramal Pharma operates through three divisions: Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and the Consumer Products Division (CPD). PPS acts as a contract development and manufacturing organization (CDMO), offering development and manufacturing services across the drug lifecycle for clients in North America, Europe, and Asia. PCC specializes in complex hospital generics, especially inhaled anesthetics, serving the USA, Europe, and more than 100 countries. CPD markets consumer health brands in India, including Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri Activ, and aims to provide reliable development, manufacturing, and distribution capabilities to meet customer needs.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
India
Founded
2020
Get referred to Piramal Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- April 28, 2026 FY26 revenue held at ₹8,869 crore; Kenalog adds $30-40 million annualized sales.
- Q4 FY26 cleared 30 inspections, including two US FDA visits without OAI findings.
- FY26 capex reached $94 million, while Lexington and Riverview expansions advanced toward FY27.
What critics are saying
- February 2026 Dahej closure over alleged hazardous dumping exposes Piramal to recurring plant shutdowns.
- Q4 FY26 growth suffered inventory destocking, slower early-stage orders, and weak ex-US anesthesia demand.
- Dahej shutdown plus repeat FDA findings can cripple PPS and PCC.
What makes Piramal Pharma unique
- Yapan Bio subsidiary deepens PPS biologics and ADC capabilities across vaccines, gene therapies, and ADCelerate.
- Piramal sells in 100-plus countries through 17 facilities and 6,000 hospitals.
- Kenalog and inhaled-anesthetic expertise combine complex manufacturing with entrenched hospital-channel distribution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Stock Options
Company News
Piramal Pharma Limited completes acquisition of controlling stake in Yapan Bio Private Limited. Aug 18, 2026, 15:36 ET * Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing. * This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services. MUMBAI, India, Aug. 18, 2026 /PRNewswire/ - Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL. Finalized on August 18, 2026, the acquisition marks a major step forward in PPL's long-range plan to expand its presence in the biologics sector. With the finalization of this deal, PPL will fully embed the subsidiary's advanced large molecule capabilities into its integrated service offering, enabling the Company to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency. The subsidiary will continue to operate within the structure of Piramal Pharma Solutions (PPS), the CDMO arm of PPL. Yapan Bio also directly supports ADCelerate(TM)- PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate(TM) and reinforces PPL's ability to deliver life-saving ADCs to market with speed and consistency. "This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action," said Peter DeYoung, CEO, Piramal Global Pharma. "By integrating Yapan Bio's specialized expertise into our global network, we're empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need." About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. SOURCE Piramal Pharma Solutions
Piramal Pharma has acquired an additional 40.67% stake in Yapan Bio for ₹76 crore, increasing its shareholding from 33.33% to 74%. The Mumbai-based pharmaceutical company purchased 146,400 equity shares, converting Yapan Bio from an associate company to a subsidiary. Yapan Bio, founded in 2019, is a Contract Development and Manufacturing Organisation specialising in vaccines and biologics. The company reported revenues of ₹26.91 crore, ₹54.40 crore, and ₹26.34 crore for fiscal years 2024, 2025, and 2026 respectively. The acquisition strengthens Piramal Pharma's biologics capabilities and expands its integrated service offerings. The company announced its intention to exercise this call option in August 2026, completing the transaction as disclosed in a regulatory filing to the National Stock Exchange.
Piramal Pharma Ltd invested INR 101.77 crore in Hyderabad-based Yapan Bio Pvt Ltd in December 2021, acquiring a 27.78% equity stake. The investment aimed to strengthen Piramal Pharma Solutions' CDMO capabilities in biologics and vaccines, particularly for large molecule development and manufacturing for human clinical trials. In April 2022, Piramal increased its stake by 5.55% for Rs 20.35 crore, bringing total ownership to 33.33% by March 2023. The company's FY2023 filings showed Yapan's share of loss at Rs 0.20 crore. In October 2022, Yapan expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, as part of a $1 million expansion plan. The facility supports end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. Yapan's services are marketed through Piramal Pharma Solutions.
Piramal Pharma expects to accelerate earnings growth over the next two to three years, driven by rising demand for complex drugs including targeted cancer therapies, chairperson Nandini Piramal said. The Indian drugmaker, which derives 55% of revenue from contract manufacturing, aims for early-to-mid-teens revenue growth after reporting a 3% drop in fiscal 2026. The company is prioritising higher-value segments, particularly antibody-drug conjugates for cancer treatment, as global biotech funding into Indian contract manufacturers rebounds. Biotech funding in the second half of 2024 was 80% higher year-on-year, translating into increased order inflows. Piramal is avoiding generic weight-loss drug ingredients due to intense competition and falling prices. The company's contract manufacturing revenue fell 10% last year, causing margins to shrink from 17% to 13%.
Piramal Pharma Limited announced results for Q4 and full-year FY26, reporting revenue growth impacted by inventory destocking, slower early-stage order inflows and softer inhalation anesthesia traction in ex-US markets. The company recognised an impairment loss of ₹176 crore on intangible assets under development. The pharmaceutical company invested $94 million in capex during FY26, with Lexington and Riverview expansions progressing. Net debt remained flat compared to FY25. Key developments included completing the Kenalog acquisition for $35 million upfront consideration plus up to $65 million contingent payment. The Consumer Healthcare division's Power Brands grew 24% year-on-year, whilst e-commerce sales surged 48%, contributing 27% to segment revenue. Chairperson Nandini Piramal stated all three business segments are positioned to deliver growth in FY27.